|

7 Psychedelic Trend Predictions for 2021

Psychedelic Trend Predictions 2021
Photo by Annie Spratt on Unsplash

While most of us are eager to put 2020 behind us, a few industries had banner years during lockdown. Pizza delivery and Zoom subscriptions may top the list but it was also a huge year for psychedelics. From major legislative victories to a record number of companies going public to big-name celeb endorsements, 2020 was, to say the least, one heck of a trip. 

Credit in part, at least, can go to the pandemic itself. As we all hunkered down and sheltered at home trying to wrap our heads around the crisis, for some, it became an eye-opener. Many were nudged toward inner reflection and an open mind to new possibilities. A record number of Americans hit the polls this election bringing two key victories for psychedelics as a result. The nation’s capital voted to decriminalize psychedelics and Oregon voted to decriminalize psychedelics and legalize therapeutic psilocybin use.

The momentum is snowballing, and 2021 will be even bigger and better for psychedelics. After a year like 2020, it’s hard to know what the next year will bring. But we’ve got a feeling it’s going to be quite the ride for psychedelics.

Psychedelic Trend Predictions for 2021

Photo by Headway on Unsplash

1. Big Investments 

The investment capital was flowing into psychedelics in 2020, and it’s going to continue well into 2021. As the psychedelic market is expected to reach $7 billion by 2027, the industry is ripe for growth with innovative developments in therapies, treatment, tech, distribution, and more. Look for more big-name investors like Peter Thiel and Shark Tank’s Kevin O’Leary (“Mr. Wonderful”) to invest in psychedelics.

Publicly-Traded Psychedelic Stocks

2. Public Companies

Dozens of psychedelic companies went public in 2020, and dozens more will open up their stock to public trading in 2021. Expect to see more innovative offerings, partnerships, and mergers as companies position themselves for trading.

Photo by Element5 Digital on Unsplash

3. Changing Policies

While Oregon was the first state to take major measures in normalizing psychedelics, it most certainly won’t be the last. California is currently working on legislation that could decriminalize psychedelics across the state. Santa Cruz and Oakland currently have local laws in place that deprioritize the substances but a statewide law could help pave the way for Federal decriminalization laws.

Public Psilocybin Depression Treatment Program

4. Innovative Therapies

Scientists and doctors are hard at work identifying and testing compounds in all manner of psychedelic substances. But expect to see these treatments used in innovative clinical settings or in partnership with other healing modalities like sound therapy, yoga, meditation, or even sensory deprivation.

Psychedelics Saved Former NBA Star Lamar Odom

5. Psychedelic Celebrities 

Will Oprah try MDMA? What if Serena Williams uses psilocybin during a Grand Slam? Or Donald Trump recovers from his election loss with ketamine? While these scenarios aren’t quite likely (you never know, though), it is possible we’ll see more celebrities coming out of the psychedelic closet than ever before. 2020 saw a record number of celebrities and athletes come forward about how they were helped by psychedelics. We can expect even more coming forward and helping to normalize not just the conversation around psychedelics but around the main issues they treat: mental health conditions.

Psychedelic Business News Spotlight

6. Psychedelic Marketing

While psychedelic imagery is nothing new to Madison Avenue when it comes to selling products from burgers to perfume, how will marketers sell psychedelics? Just like bans on ads for cannabis and tobacco, psychedelic marketing has to get creative. Fortunately, social media is still fair play. And with marketing budgets to spend, psychedelic companies will let their creativity shine. Look for them leaning into both the stigmas around psychedelic culture and the unchartered territory the newly decriminalized or fully legal substances offer. 

Photo by Cade Renfroe on Unsplash

7. COVID Relief

If 2020 hasn’t been a challenging year for you, congratulations. It’s taken enormous tolls on most of us — whether financially, physically, or emotionally. And these strains may last long after the vaccine has been widely distributed. For those who’ve suffered the loss of loved ones, businesses, or other traumas related to the devastation brought by the pandemic, psychedelic therapy may offer relief. People suffering from anxiety or depression may try any number of therapies to bring some healing, and with psychedelic therapies now on the menu in some parts of the world, 2021 is likely to see an uptick in COVID-related requests.

Similar Posts

  • Bad NEWS for NUMI, FieldTrip and J&J || Esketamine to Treat DEPRESSION Study Results And More

    Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG esketamine study results, new 5MEO-DMT tests and Updates on the decriminalization efforts in California and Texas.

    In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

    1. We’ll cover some interesting and maybe disappoint results coming from a study designed to determine whether esketamine can treat depression and their implications on some companies such as Numinus Wellness (NUMI), Field Trip Health ( FTRP) and Johnsons & Johnson (JNJ)
    2. Study looking at the creativity benefits of taking psilocybin
    3. Compass Pathways (CMPS) has amazing new price targets
    4. First ever clinical trial testing the safety profile of a compound called 5MEO – DMT
    5. A couple of updates on decriminalization efforts

    Timestapms:

    0:00 – Intro
    1:33 – Likelihood of Adverse events from Nasal Esketamine : Implications for Numinus, JNJ and Fieldtrip Health
    6:07 – Psilocybin’s effects on creativity in a new placebo-controlled neuroimaging and it’s effects on MindMed (MMED/MMEDF), Compass Pathways (CMPS), Mydecine (MYCO) , Numinus ( NUMI)
    11:25 – Researchers to team up to produce the first ever 5-meo-DMT Psychedelic Training Program
    12:28 – California bill To Legalize Possession of Psychedelics Clears Second Senate Committee
    14:26 – Rick Perry supports the Texas Capital to study psychedelic drugs from PTSD in veterans.

    I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa
    ​…

    https://benzinga.grsm.io/thepsychedel

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #PsychedelicStocks ​#Numi #Mindmed